The analyses for which Dr. Warburton was contracted "...included investigation of harmful side-effects, including mortality, and risk assessment of drugs purchased by the province through its programs, and had the potential of disrupting financially significant payments to large pharmaceutical companies, many of whom were major contributors to the Liberal Party who formed the government in the Province" (see lawsuit here).
Dr. Warburton was required to conduct these analyses on very profitable medications (see below) after the Province had developed programs and financing to attract these companies to British Columbia. Additionally, the Liberal Party received sizable donations from these same drug companies. The lawsuit states that the Province sought to "...end the investigation of harmful effects of drugs which risk leading to diminishing payments to their political contributors."
To maintain good standing with the pharmaceutical companies and to prevent the potential loss of sales as a result of the research findings, Dr. Warburton's access to the data sets, which he was contracted to analyze, were revoked. He was then fired and the Province cut funding to other drug safety and analysis programs, such as Therapeutics Initiative at the University of British Columiba, that conducted similar work.
Dr. Warburton was contracted to conduct analyses on data for the following medications:
Abilify (aripiprazole) - Bristol Myers Squibb
Seroquel (quetiapine) - AstraZeneca Canada Inc.
Risperidal (risperidone) - Janssen Inc.
Zeldox (ziprasidone) - Pfizer Canada Inc.
Invega (paliperidone) - Janssen Inc.
Clozaril (clorzapine) - Novartis Pharmaceuticals Canada Inc.
Read the lawsuit here: Warburton v. Province of British Columbia and MacDiarmid, 2013
Drug Safety Research in Canada and Political Donations
Canadian Agency Freezes Funding To Drug Safety Group